octisalate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
analgesic anti-inflammatory	4241	118-60-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: octisalate octyl salicylate	Molecular weight: 250.34 Formula: C15H22O3 CLOGP: 5.91 LIPINSKI: 1 HAC: 3 HDO: 1 TPSA: 46.53 ALOGS: -4.02 ROTB: 8

Molecule

Description

Molfile Inchi Smiles

Synonyms:

octisalate
octyl salicylate

Molecular weight: 250.34
Formula: C15H22O3
CLOGP: 5.91
LIPINSKI: 1
HAC: 3
HDO: 1
TPSA: 46.53
ALOGS: -4.02
ROTB: 8

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
None	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	730.37	15.93	224	8240	24152	63456406
Chronic sinusitis	225.77	15.93	79	8385	12764	63467794
Paraesthesia oral	198.06	15.93	80	8384	19176	63461382
Procedural pain	185.97	15.93	79	8385	21490	63459068
Body tinea	113.77	15.93	30	8434	1855	63478703
Drug ineffective	112.59	15.93	348	8116	1044417	62436141
Vaginal flatulence	110.05	15.93	33	8431	3260	63477298
Inhibitory drug interaction	101.51	15.93	30	8434	2819	63477739
Proctitis	97.60	15.93	34	8430	5407	63475151
Radiculopathy	96.21	15.93	38	8426	8573	63471985
Infection susceptibility increased	95.25	15.93	30	8434	3491	63477067
Therapeutic product effect incomplete	94.43	15.93	99	8365	124957	63355601
Female genital tract fistula	93.81	15.93	36	8428	7523	63473035
Dyspepsia	79.08	15.93	82	8382	102114	63378444
Vaginal discharge	76.94	15.93	33	8431	9165	63471393
Glucose tolerance impaired	76.91	15.93	30	8434	6547	63474011
Poor quality sleep	76.68	15.93	42	8422	19893	63460665
Purpura	67.12	15.93	32	8432	11353	63469205
Impaired quality of life	61.33	15.93	32	8432	13751	63466807
Bone density decreased	56.78	15.93	31	8433	14581	63465977
Colitis ulcerative	54.03	15.93	37	8427	26054	63454504
Hyperlipidaemia	53.40	15.93	33	8431	19538	63461020
Impaired work ability	51.61	15.93	31	8433	17444	63463114
Oral candidiasis	51.20	15.93	34	8430	22764	63457794
Frequent bowel movements	48.50	15.93	33	8431	22989	63457569
Skin disorder	45.49	15.93	35	8429	29472	63451086
Local anaesthetic systemic toxicity	43.41	15.93	12	8452	887	63479671
Oral herpes	42.56	15.93	32	8432	26042	63454516
Pyrexia	42.22	15.93	148	8316	470330	63010228
Removal of foreign body	41.99	15.93	7	8457	41	63480517
Tracheal deviation	39.34	15.93	8	8456	154	63480404
Weight decreased	37.84	15.93	101	8363	276697	63203861
Phrenic nerve paralysis	37.82	15.93	8	8456	188	63480370
Colitis	37.59	15.93	39	8425	48489	63432069
Rectal haemorrhage	35.48	15.93	38	8426	48992	63431566
Herpes zoster	32.35	15.93	47	8417	82415	63398143
Haematochezia	31.07	15.93	37	8427	53507	63427051
Cellulitis	26.90	15.93	43	8421	81915	63398643
Infusion related reaction	26.18	15.93	82	8382	245439	63235119
Foreign body in respiratory tract	23.76	15.93	6	8458	312	63480246
Anaphylactic shock	22.01	15.93	21	8443	23612	63456946
Cataract	21.62	15.93	32	8432	57021	63423537
Rheumatoid arthritis	21.35	15.93	4	8460	253815	63226743
Constipation	21.16	15.93	72	8392	224871	63255687
Alopecia	20.03	15.93	10	8454	337526	63143032
Nausea	19.93	15.93	187	8277	854284	62626274
Purtscher retinopathy	18.91	15.93	4	8460	94	63480464
Drug intolerance	18.53	15.93	9	8455	308652	63171906
Systemic lupus erythematosus	18.20	15.93	3	8461	208915	63271643
Jarisch-Herxheimer reaction	18.05	15.93	5	8459	372	63480186
Anaemia	17.92	15.93	82	8382	293348	63187210
Chemical burn	17.46	15.93	5	8459	420	63480138
Foetal exposure during delivery	16.86	15.93	4	8460	160	63480398
Dermatophytosis	16.23	15.93	4	8460	188	63480370

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anal inflammation	75.09	17.78	20	4663	1280	34950968
SARS-CoV-2 test negative	65.17	17.78	17	4666	1003	34951245
Proctalgia	52.66	17.78	22	4661	5701	34946547
Accident	48.46	17.78	20	4663	5027	34947221
Appendicolith	47.06	17.78	23	4660	8578	34943670
Cardiogenic shock	44.09	17.78	33	4650	26585	34925663
Ventricular fibrillation	43.79	17.78	31	4652	22923	34929325
Appendicitis	40.39	17.78	25	4658	14782	34937466
Removal of foreign body	35.56	17.78	6	4677	38	34952210
Haemorrhoids	33.28	17.78	22	4661	14553	34937695
Cardiac arrest	30.84	17.78	50	4633	96109	34856139
Body temperature increased	27.57	17.78	21	4662	17347	34934901
Ascites	26.63	17.78	32	4651	46539	34905709
Stress	24.52	17.78	25	4658	30322	34921926
Constipation	22.77	17.78	54	4629	136928	34815320
Hyponatraemia	21.25	17.78	39	4644	82652	34869596
Abdominal distension	20.92	17.78	32	4651	58460	34893788
Methaemoglobinaemia	20.86	17.78	10	4673	3571	34948677
Multiple organ dysfunction syndrome	19.53	17.78	36	4647	76530	34875718
Administration related reaction	18.69	17.78	4	4679	99	34952149
Blood phosphorus increased	18.46	17.78	12	4671	7709	34944539
Anaphylactic shock	18.38	17.78	16	4667	15925	34936323
Blood uric acid increased	18.35	17.78	13	4670	9611	34942637

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	208.16	14.76	74	11761	11222	79721331
Chronic sinusitis	205.20	14.76	76	11759	12950	79719603
Paraesthesia oral	184.95	14.76	80	11755	20391	79712162
Procedural pain	166.31	14.76	77	11758	23007	79709546
Body tinea	111.06	14.76	30	11805	1824	79730729
Vaginal flatulence	110.11	14.76	32	11803	2543	79730010
Female genital tract fistula	94.58	14.76	35	11800	5940	79726613
Infection susceptibility increased	90.44	14.76	30	11805	3691	79728862
Inhibitory drug interaction	88.99	14.76	31	11804	4422	79728131
Proctitis	84.92	14.76	33	11802	6399	79726154
Radiculopathy	84.66	14.76	36	11799	8788	79723765
Therapeutic product effect incomplete	83.59	14.76	104	11731	141541	79591012
Vaginal discharge	76.78	14.76	32	11803	7431	79725122
Glucose tolerance impaired	67.81	14.76	30	11805	8054	79724499
Anal inflammation	66.62	14.76	19	11816	1411	79731142
Dyspepsia	66.02	14.76	81	11754	108606	79623947
Poor quality sleep	64.85	14.76	41	11794	22681	79709872
Removal of foreign body	63.89	14.76	11	11824	71	79732482
Impaired quality of life	56.81	14.76	32	11803	14354	79718199
Bone density decreased	56.28	14.76	31	11804	13316	79719237
SARS-CoV-2 test negative	54.05	14.76	16	11819	1355	79731198
Hyperlipidaemia	50.43	14.76	37	11798	26056	79706497
Purpura	50.21	14.76	33	11802	19494	79713059
Local anaesthetic systemic toxicity	49.08	14.76	14	11821	1040	79731513
Appendicolith	44.93	14.76	23	11812	8528	79724025
Impaired work ability	42.83	14.76	30	11805	19651	79712902
Skin disorder	41.86	14.76	37	11798	33906	79698647
Oral herpes	40.14	14.76	33	11802	27421	79705132
Ventricular fibrillation	39.77	14.76	35	11800	31891	79700662
Constipation	39.07	14.76	111	11724	282939	79449614
Pyrexia	39.02	14.76	201	11634	678508	79054045
Proctalgia	38.82	14.76	22	11813	9979	79722574
Anaphylactic shock	38.07	14.76	36	11799	35960	79696593
Oral candidiasis	37.95	14.76	33	11802	29595	79702958
Tracheal deviation	37.60	14.76	8	11827	173	79732380
Colitis ulcerative	37.23	14.76	35	11800	34707	79697846
Frequent bowel movements	36.03	14.76	32	11803	29507	79703046
Accident	35.83	14.76	20	11815	8811	79723742
Cardiogenic shock	33.46	14.76	36	11799	41878	79690675
Chemical burn	32.74	14.76	9	11826	584	79731969
Phrenic nerve paralysis	32.56	14.76	8	11827	333	79732220
Appendicitis	32.52	14.76	26	11809	20768	79711785
Foreign body	31.77	14.76	13	11822	2881	79729672
Foreign body in respiratory tract	31.19	14.76	8	11827	397	79732156
Herpes zoster	29.48	14.76	51	11784	93032	79639521
Methaemoglobinaemia	29.35	14.76	15	11820	5542	79727011
Cardiac arrest	26.20	14.76	70	11765	172026	79560527
Completed suicide	26.03	14.76	3	11832	245764	79486789
Abdominal distension	25.00	14.76	55	11780	119595	79612958
Colitis	24.31	14.76	41	11794	73266	79659287
Kounis syndrome	23.90	14.76	12	11823	4270	79728283
Haemorrhoids	23.22	14.76	25	11810	29103	79703450
Infusion related reaction	23.17	14.76	81	11754	230156	79502397
Rectal haemorrhage	21.84	14.76	40	11795	76260	79656293
Haematochezia	21.46	14.76	43	11792	87602	79644951
Rheumatoid arthritis	20.97	14.76	3	11832	208467	79524086
Cataract	20.94	14.76	35	11800	62085	79670468
Weight decreased	20.18	14.76	105	11730	355093	79377460
Ascites	19.62	14.76	38	11797	75524	79657029
Nausea	19.44	14.76	222	11613	956974	78775579
Purtscher retinopathy	17.48	14.76	4	11831	122	79732431
Cellulitis	17.24	14.76	45	11790	109015	79623538
Abdominal pain	16.78	14.76	107	11728	389462	79343091
Myasthenia gravis	16.25	14.76	13	11822	10386	79722167
Anaesthetic complication	15.92	14.76	8	11827	2851	79729702
Malaise	15.56	14.76	125	11710	489744	79242809
Arthritis bacterial	15.49	14.76	12	11823	9154	79723399
Blood uric acid increased	15.35	14.76	14	11821	13346	79719207
Administration related reaction	14.91	14.76	4	11831	237	79732316

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.9	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4X49Y0596W	UNII
4025698	VUID
N0000179486	NUI
D05226	KEGG_DRUG
4020295	VANDF
4025698	VANDF
C0304632	UMLSCUI
CHEBI:88639	CHEBI
CHEMBL1329203	ChEMBL_ID
8364	PUBCHEM_CID
DB11062	DRUGBANK_ID
7940	INN_ID
91327	RXNORM
006876	NDDF
29622009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TOTAL DEFENSE REPAIR BROAD SPECTRUM SPF 34 Sunscreen	HUMAN OTC DRUG LABEL	3	0023-5494	LOTION	30 mg	TOPICAL	OTC monograph not final	12 sections
TOTAL DEFENSE REPAIR BROAD SPECTRUM SPF 34 Sunscreen	HUMAN OTC DRUG LABEL	3	0023-5494	LOTION	30 mg	TOPICAL	OTC monograph not final	12 sections
TOTAL DEFENSE REPAIR BROAD SPECTRUM SPF 34 Sunscreen (Tinted)	HUMAN OTC DRUG LABEL	4	0023-5497	LOTION	30 mg	TOPICAL	OTC monograph not final	12 sections
TOTAL DEFENSE REPAIR BROAD SPECTRUM SPF 34 Sunscreen (Tinted)	HUMAN OTC DRUG LABEL	4	0023-5497	LOTION	30 mg	TOPICAL	OTC monograph not final	12 sections
TOTAL DEFENSE REPAIR BROAD SPECTRUM SPF 50 Sunscreen	HUMAN OTC DRUG LABEL	4	0023-5501	LOTION	50 mg	TOPICAL	OTC monograph not final	8 sections
Purpose	HUMAN OTC DRUG LABEL	3	0187-5500	LOTION	50 mg	TOPICAL	OTC monograph not final	9 sections
Cetaphil Daily Facial Moisturizer with suncreen SPF 35	HUMAN OTC DRUG LABEL	4	0299-4113	LOTION	48 mg	TOPICAL	OTC monograph final	12 sections
Cetaphil Daily Facial Moisturizer with suncreen SPF 35	HUMAN OTC DRUG LABEL	4	0299-4113	LOTION	48 mg	TOPICAL	OTC monograph final	12 sections
Cetaphil Healthy Radiance Whipped Day Cream Broad Spectrum SPF 30	HUMAN OTC DRUG LABEL	4	0299-4118	LOTION	50 mg	TOPICAL	OTC monograph final	12 sections
Cetaphil Healthy Radiance Whipped Day Cream Broad Spectrum SPF 30	HUMAN OTC DRUG LABEL	4	0299-4118	LOTION	50 mg	TOPICAL	OTC monograph final	12 sections
Cetaphil Oil Absorbing SPF 30	HUMAN OTC DRUG LABEL	3	0299-4123	LOTION	5 g	TOPICAL	OTC monograph final	8 sections
Cetaphil Oil Absorbing SPF 30	HUMAN OTC DRUG LABEL	3	0299-4123	LOTION	5 g	TOPICAL	OTC monograph final	8 sections
Differin Oil Absorbing Moisturizer SPF 30	HUMAN OTC DRUG LABEL	3	0299-4133	LOTION	5 g	TOPICAL	OTC monograph final	9 sections
Cetaphil Oil Absorbing SPF 30	HUMAN OTC DRUG LABEL	3	0299-4134	LOTION	5 g	TOPICAL	OTC monograph final	8 sections
Cetaphil Healthy Renew Day Cream Broad Spectrum SPF 30	HUMAN OTC DRUG LABEL	4	0299-4136	LOTION	48 mg	TOPICAL	OTC monograph final	12 sections
Cetaphil PRO Oil Absorbing SPF 30	HUMAN OTC DRUG LABEL	3	0299-4313	LOTION	5 g	TOPICAL	OTC monograph final	8 sections
Differin Oil Absorbing Moisturizer SPF 30	HUMAN OTC DRUG LABEL	3	0299-4607	LOTION	5 g	TOPICAL	OTC monograph final	9 sections
Differin Oil Absorbing Moisturizer SPF 30	HUMAN OTC DRUG LABEL	3	0299-4607	LOTION	5 g	TOPICAL	OTC monograph final	9 sections
Cetaphil Daily Facial Moisturizer with suncreen SPF 50	HUMAN OTC DRUG LABEL	5	0299-4930	LOTION	50 mg	TOPICAL	OTC monograph final	11 sections
Cetaphil Daily Facial Moisturizer with suncreen SPF 50	HUMAN OTC DRUG LABEL	5	0299-4930	LOTION	50 mg	TOPICAL	OTC monograph final	11 sections
Almay Smart Shade CC Cream	HUMAN OTC DRUG LABEL	3	0311-0705	LIQUID	5 mg	TOPICAL	OTC monograph final	6 sections
Almay Anti Aging Lip Care SPF 20	HUMAN OTC DRUG LABEL	5	0311-0709	LIPSTICK	5 mg	TOPICAL	OTC monograph final	8 sections
Almay Best Blend Forever Makeup	HUMAN OTC DRUG LABEL	4	0311-0719	LOTION	5 mg	TOPICAL	OTC monograph final	5 sections
Almay Healthy Biome Makeup	HUMAN OTC DRUG LABEL	5	0311-0723	EMULSION	5 mg	TOPICAL	OTC monograph final	7 sections
Blue Lizard Kids SPF 50 Sunscreen	HUMAN OTC DRUG LABEL	3	0316-2062	LOTION	55.50 mg	TOPICAL	OTC monograph not final	9 sections
Blue Lizard Kids SPF 50 Sunscreen	HUMAN OTC DRUG LABEL	3	0316-2062	LOTION	55.50 mg	TOPICAL	OTC monograph not final	9 sections
Blue Lizard Active SPF 50 Sunscreen	HUMAN OTC DRUG LABEL	3	0316-2072	LOTION	55.50 mg	TOPICAL	OTC monograph not final	9 sections
Blue Lizard Active SPF 50 Sunscreen	HUMAN OTC DRUG LABEL	3	0316-2072	LOTION	55.50 mg	TOPICAL	OTC monograph not final	9 sections
Blue Lizard Sport SPF 50 Sunscreen	HUMAN OTC DRUG LABEL	3	0316-2075	LOTION	55.50 mg	TOPICAL	OTC monograph not final	9 sections
Blue Lizard Sport SPF 50 Sunscreen	HUMAN OTC DRUG LABEL	3	0316-2075	LOTION	55.50 mg	TOPICAL	OTC monograph not final	9 sections